12:00 AM
 | 
Jun 25, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Tradjenta: Phase III data

A Phase III trial in 241 Type II diabetics aged >=70 years inadequately controlled with metformin and/or sulfonylurea and/or insulin showed that once-daily 5 mg Tradjenta as an add-on therapy significantly reduced mean HbA1c from baseline to week 24...

Read the full 175 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >